- Home
- ADAP vs PRPO Comparison
ADAP vs PRPO Comparison
Compare ADAP & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAP
- PRPO
- Stock Information
- Founded
- ADAP 2008
- PRPO N/A
- Country
- ADAP United Kingdom
- PRPO United States
- Employees
- ADAP N/A
- PRPO N/A
- Industry
- ADAP Biotechnology: Pharmaceutical Preparations
- PRPO Biotechnology: Laboratory Analytical Instruments
- Sector
- ADAP Health Care
- PRPO Industrials
- Exchange
- ADAP Nasdaq
- PRPO Nasdaq
- Market Cap
- ADAP 21.3M
- PRPO 22.0M
- IPO Year
- ADAP 2015
- PRPO N/A
- Fundamental
- Price
- ADAP $0.06
- PRPO $19.51
- Analyst Decision
- ADAP Hold
- PRPO
- Analyst Count
- ADAP 6
- PRPO 0
- Target Price
- ADAP $1.02
- PRPO N/A
- AVG Volume (30 Days)
- ADAP 62.3M
- PRPO 18.4K
- Earning Date
- ADAP 11-12-2025
- PRPO 11-05-2025
- Dividend Yield
- ADAP N/A
- PRPO N/A
- EPS Growth
- ADAP N/A
- PRPO N/A
- EPS
- ADAP N/A
- PRPO N/A
- Revenue
- ADAP $65,084,999.00
- PRPO $21,242,000.00
- Revenue This Year
- ADAP N/A
- PRPO N/A
- Revenue Next Year
- ADAP $52.35
- PRPO N/A
- P/E Ratio
- ADAP N/A
- PRPO N/A
- Revenue Growth
- ADAP N/A
- PRPO 27.05
- 52 Week Low
- ADAP $0.04
- PRPO $3.90
- 52 Week High
- ADAP $1.17
- PRPO $22.38
- Technical
- Relative Strength Index (RSI)
- ADAP 38.42
- PRPO 69.65
- Support Level
- ADAP $0.06
- PRPO $19.40
- Resistance Level
- ADAP $0.07
- PRPO $22.38
- Average True Range (ATR)
- ADAP 0.01
- PRPO 1.31
- MACD
- ADAP 0.01
- PRPO 0.48
- Stochastic Oscillator
- ADAP 53.33
- PRPO 65.56
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.